1. Subjects will be enrolled in the study if they meet all the following criteria: <br/ > <br/ >2. Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements <br/ > <br/ >3. Male or female patients between 18 and 60 years of age (both inclusive) <br/ > <br/ >4. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected â?¤5 days prior to randomization) <br/ > <br/ >5. Note: If rapid antigen test has been performed and patient found positive then RT-PCR will be performed prior to randomization. <br/ > <br/ >6. Patients with mild COVID-19 and have following symptoms and signs prior to randomization â?¤5 days prior to randomization <br/ > <br/ >7. Upper respiratory tract symptoms (&/or fever) without shortness of breath or hypoxia. <br/ > <br/ >8. As defined by AIIMS/ ICMR-COVID-19 National Task Force/Joint Monitoring Group (Directorate General Of Health Services) Ministry of Health & Family Welfare, Government of India- clinical guidance for management of adult COVID-19 patients, dated 22-Apr-2021. <br/ > <br/ >9. Is willing and able to take oral medication <br/ > <br/ >10. Willingness to comply with study instructions for its duration as indicated by written informed consent from the patient <br/ > <br/ >

1. Subjects will be enrolled in the study if they meet all the following criteria: <br/ > <br/ >2. Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements <br/ > <br/ >3. Male or female patients between 18 and 60 years of age (both inclusive) <br/ > <br/ >4. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected â?¤5 days prior to randomization) <br/ > <br/ >5. Note: If rapid antigen test has been performed and patient found positive then RT-PCR will be performed prior to randomization. <br/ > <br/ >6. Patients with mild COVID-19 and have following symptoms and signs prior to randomization â?¤5 days prior to randomization <br/ > <br/ >7. Upper respiratory tract symptoms (&/or fever) without shortness of breath or hypoxia. <br/ > <br/ >8. As defined by AIIMS/ ICMR-COVID-19 National Task Force/Joint Monitoring Group (Directorate General Of Health Services) Ministry of Health & Family Welfare, Government of India- clinical guidance for management of adult COVID-19 patients, dated 22-Apr-2021. <br/ > <br/ >9. Is willing and able to take oral medication <br/ > <br/ >10. Willingness to comply with study instructions for its duration as indicated by written informed consent from the patient <br/ > <br/ >

1. Subjects will be enrolled in the study if they meet all the following criteria: <br/ > <br/ >2. Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements <br/ > <br/ >3. Male or female patients between 18 and 60 years of age (both inclusive) <br/ > <br/ >4. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected â?¤5 days prior to randomization) <br/ > <br/ >5. Note: If rapid antigen test has been performed and patient found positive then RT-PCR will be performed prior to randomization. <br/ > <br/ >6. Patients with mild COVID-19 and have following symptoms and signs prior to randomization â?¤5 days prior to randomization <br/ > <br/ >7. Upper respiratory tract symptoms (&/or fever) without shortness of breath or hypoxia. <br/ > <br/ >8. As defined by AIIMS/ ICMR-COVID-19 National Task Force/Joint Monitoring Group (Directorate General Of Health Services) Ministry of Health & Family Welfare, Government of India- clinical guidance for management of adult COVID-19 patients, dated 22-Apr-2021. <br/ > <br/ >9. Is willing and able to take oral medication <br/ > <br/ >10. Willingness to comply with study instructions for its duration as indicated by written informed consent from the patient <br/ > <br/ >

1. Subjects will be enrolled in the study if they meet all the following criteria: <br/ > <br/ >2. Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements <br/ > <br/ >3. Male or female patients between 18 and 60 years of age (both inclusive) <br/ > <br/ >4. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected â?¤5 days prior to randomization) <br/ > <br/ >5. Note: If rapid antigen test has been performed and patient found positive then RT-PCR will be performed prior to randomization. <br/ > <br/ >6. Patients with mild COVID-19 and have following symptoms and signs prior to randomization â?¤5 days prior to randomization <br/ > <br/ >7. Upper respiratory tract symptoms (&/or fever) without shortness of breath or hypoxia. <br/ > <br/ >8. As defined by AIIMS/ ICMR-COVID-19 National Task Force/Joint Monitoring Group (Directorate General Of Health Services) Ministry of Health & Family Welfare, Government of India- clinical guidance for management of adult COVID-19 patients, dated 22-Apr-2021. <br/ > <br/ >9. Is willing and able to take oral medication <br/ > <br/ >10. Willingness to comply with study instructions for its duration as indicated by written informed consent from the patient <br/ > <br/ >